印度肺炎球菌结合疫苗的影响与成本效果
本研究以2018至2027年10个出生队列为基础,用UNIVAC确定性静态队列模型比较全国引入PCV13与不接种的代价效果。结果显示每避免一个DALY需额外支出467美元(31666印度卢比),低于印度人均GDP,概率敏感性分析ICER为649美元(95%CI 374-1161),结论为PCV项目极具成本效果。
要点
- PCV13接种每避免一个DALY额外花费467美元(31666印度卢比),低于人均GDP。
- 概率敏感性分析ICER为649美元(95%CI 374-1161)。
核心结论
- PCV项目在印度是极具成本效果的干预,支持将其纳入常规免疫规划以降低五岁以下儿童发病和死亡。
研究设计与样本
- 采用UNIVAC确定性静态队列模型,对2018至2027年10个出生队列比较全国PCV13接种与不接种,参数取保守估计,评价生命前五年的死亡、疾病事件率、疫苗效力与覆盖预测、系统与卫生保健成本。
主要发现
- 引入PCV接种项目每避免一个DALY可额外花费467美元(31666印度卢比),低于印度人均GDP。
- 概率敏感性分析显示PCV的ICER为649美元(44008印度卢比),95%CI为374至1161美元。
关键数值与推荐
- 以人均GDP作为支付意愿阈值,从政府视角计算PCV干预具有成本效果的概率。
- 成本效果以增量成本效果比(ICER)报告。
临床怎么用
- 结果为印度全国引入PCV13提供经济学依据,可支持部分邦先行纳入并逐步推广至全国常规免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: World Health Organization has recommended the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunisation programme of all the countries in the world. In lieu of its introduction in India, there is a need to generate evidence on cost-effectiveness of this vaccine. The current study looks into the impact and cost-effectiveness of PCV vaccine in India. METHODS: We evaluated the cost effectiveness of implementation of PCV 13 vaccination program at national level by comparing with no vaccination program for a period of 10 birth cohorts from 2018 to 2027. UNIVAC, a deterministic static cohort model is developed by giving the conservative estimates of vaccine program related to mortality, disease event rates, vaccine efficacy and coverage projections, system and health care costs for the first five years of life. Cost effectiveness is reported as Incremental Cost Effectiveness Ratio (ICER). Further scenario and sensitivity analysis were done. Probability of PCV intervention to be cost effective at a willingness to pay (WTP) threshold equal to per capita gross domestic product (GDP) is calculated using the government perspective. RESULTS: We found that the introduction of PCV vaccination program can cost an additional $467 (INR 31,666) for averting per DALY which is less than one time GDP per capita of India. Even with the most unfavourable scenario for PCV vaccine, cost per DALY averted is found to be $2323 (INR 1,57,520) which is still a cost effective intervention in India. Probabilistic sensitivity analysis found the ICER for PCV to be $649 (INR 44,008) with 95% CI: $374-$1161. CONCLUSION: This study shows that the PCV program is a highly cost effective intervention and justifies the introduction of PCV into routine immunisation schedule in some of the states and recommends introducing it throughout the country to reduce morbidity and mortality among the under-five children.
引用
- Krishnamoorthy Y, Eliyas SK, Nair NP, et al. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2018. PMID: 30587430. doi:10.1016/j.vaccine.2018.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。